COVID-19: FG Speaks On Vaccine Containing Microchip, Altar DNA

The Federal Government of Nigeria, has dismissed rumours that the expected COVID-19 vaccines in the country contains microchip and altar Human Genetic information.

This was made known by the Executive Director of the National Primary Health Care Development Agency (NPHCDA), Dr. Faisal Shuaib, at the joint national briefing of the Presidential Task Force (PTF) on COVID-19 on Monday.

Gistlover recalls that Nigeria is expecting 100,000 COVID-19 vaccines by the end of January, 2021.

The NPHCDA boss urged Nigerians to take the COVID-19 vaccines once it is available in the country.

He said: “It will not only protect Nigerians, the vaccines would also trigger an immune response that will protect the body against the virus if encountered.

“We encourage all Nigerians to get vaccinated when vaccines become accessible as the benefits of the vaccines far outweighs the potential side effects.

“The chances of spreading the disease is significantly reduced once community members are vaccinated and protected, owing to the fact that the vaccines triggers an immune response that will protect your body against the virus if encountered.

“Please note that taking the vaccine will not only protect you, it will protect your loved ones and community members against the COVID-19 disease as we worked towards developing health immunity.

“There currently seems to be growing vaccines hesitancy and this is largely caused by misinformation leading to mistrust, doubts, suspicions and conspiracy theories. We urged the public to disregard such representation from unverified sources and listen to the medical experts for confirmed information.”

Dr Shuaib insisted that COVID-19 vaccines do not contain any harmful substance, microchip and does not alter Human Genetic information.

He said, “Furthermore, any vaccine coming to Nigeria will be tested by NAFDAC and certified safe for human use before it is administered. We will like to assure all Nigerians that this verification exercise will also be applicable to the COVID-19 vaccine and NAFDAC will continue to monitor the efficacy of the vaccine even after its administration to ensure proper documentation of any side effects.”